FDA Inspection 982641 — Wuhan Biocause Pharmaceutical Development Co., Ltd.
The FDA completed an inspection of Wuhan Biocause Pharmaceutical Development Co., Ltd. on July 22, 2016 in Wuhan. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- July 22, 2016
- Fiscal Year
- 2016
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Wuhan (China)